Ocular Hypertension Clinical Trial
Official title:
Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device Via Iris Recognition Techniques
To explore an effective diagnostic tool of glaucoma through the dynamic analysis of computerized pupillary light reflex assessment device (CPLRAD) pupillography based on iris recognition techniques and investigate its feasibility in glaucoma screening.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | October 1, 2021 |
Est. primary completion date | April 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - with open angles on gonioscopy - best-corrected visual acuity =0.5 - spherical refraction within ±6.0 diopters (D), and cylinder correction within 3.0 D Exclusion Criteria: - eyes with any evidence of physical abnormality of the iris or pupils on slit-lamp examination - eyes with a history of trauma or inflammation - undergone an intraocular surgery or laser within the previous 6 months /except uncomplicated cataract surgery - using systemic or topical medications that could affect pupil responses, including pilocarpine or atropine - presence of any media opacities that prevented good quality optical coherence tomography (OCT) or fundus images - presence of any retinal or neurological disease other than glaucoma abnormal ocular motility that prevents binocular fixation (eg, nystagmus, strabismus) - with severe system diseases or psychiatric disorders |
Country | Name | City | State |
---|---|---|---|
China | Peking University Third Hosipital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Constriction Velocity in One Eye in Different Groups | The maximum constriction velocity will be calculated by the software | The test of each participant will complete the all procedures within 1 hour. | |
Primary | Maximum Dilation Velocity in One Eye in Different Groups | The maximum dilation velocity will be calculated by the software. | The test of each participant will complete the all procedures within 1 hour. | |
Primary | Pupil Constriction Amplitude(ratio) in One Eye in Different Groups | The pupil constriction amplitude(ratio) will be calculated by the software. | The test of each participant will complete the all procedures within 1 hour. | |
Primary | Baseline Pupil Size in One Eye in Different Groups | The baseline pupil size is measured before the stimulus on. | The test of each participant will complete the all procedures within 1 hour. | |
Primary | Baseline Pupil Size(BPZ) Asymmetry between Two Eyes in Different Groups | Asymmetry is calculated by a formula:
RAPD score of BPZ= 10 * log10 (baseline pupil size in right eye/baseline pupil size in left eye) |
The test of each participant will complete the all procedures within 1 hour. | |
Primary | Maximum Constriction Velocity(MCV) Asymmetry between Two Eyes in Different Groups | Asymmetry is calculated by a formula:
RAPD score of MCV= 10 * log10 (maximum constriction velocity in right eye/maximum constriction velocity in left eye) |
The test of each participant will complete the all procedures within 1 hour. | |
Primary | Maximum Dilation Velocity(MDV) Asymmetry between Two Eyes in Different Groups | Asymmetry is calculated by a formula:
RAPD score of MDV = 10 * log10 (maximum dilation velocity in right eye/maximum dilation velocity in left eye) |
The test of each participant will complete the all procedures within 1 hour. | |
Primary | Pupil Constriction Amplitude(ratio) Asymmetry between Two Eyes in Different Groups | Amplitude(ratio) is calculated by: (DIAMETER resting-DIAMETER constricted) / DIAMETER resting
Asymmetry was calculated by a formula: RAPD score of Amplitude = 10 * log10 (pupil constriction amplitude in right eye/pupil constriction amplitude in left eye) |
The test of each participant will complete the all procedures within 1 hour. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01415401 -
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
|
Phase 4 | |
Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 |